

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **Vital Innovations Holdings Limited**

### **維太創科控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6133)**

#### **INSIDE INFORMATION**

- (i) DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS;**
- (ii) POSTPONEMENT OF THE BOARD MEETING; AND**
- (iii) SUSPENSION OF TRADING**

This announcement is made by Vital Innovations Holdings Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

#### **DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS**

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors of the Company that there will be a delay in the publication of its preliminary results in respect of the financial year ended 31 December 2023 (“**2023 Annual Results**”) as additional time is required for completing certain audit procedure including collecting the external confirmations.

Pursuant to Rules 13.49(1) of the Listing Rules, the Company is required to publish an announcement in relation to its 2023 Annual Results not later than three months after the end of the financial year of the Company (i.e. on or before 31 March 2024). Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2023 Annual Results shall be based on the Company’s financial statements for the year ended 31 December 2023 which shall have been agreed with the auditor. The delay in publishing the 2023 Annual Results, if materialized, will constitute non-compliance with Rules 13.49(1) of the Listing Rules. The Board is working closely with the auditor of the Company, Confucius International CPA Limited (the “**Auditor**”) and has been using its best endeavours to assist and cooperate in order to complete the auditing process as soon as possible. Based on the recent communications with the Auditor, the Company expects that the 2023 Annual Results will be published on or before 30 April 2024.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the Auditor (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2023 at this stage as such management accounts may not accurately reflect the financial performance and position of the Group and may confuse or mislead the Shareholders and potential investors of the Company.

The Company will make further announcement(s) to provide updates on the above matters as and when appropriate in accordance with the Listing Rules and the SFO.

### **POSTPONEMENT OF THE BOARD MEETING**

Reference is made to the announcement of the Company dated 13 March 2024 in relation to the date of the meeting of the Board to be held on 26 March 2024 for the purpose of considering and approving the 2023 Annual Results and the recommendation of a final dividend, if any.

As the 2023 Annual Results will not be available for publication by 26 March 2024, the meeting of the Board for the purpose of, among other matters, considering and approving the 2023 Annual Results and its publication, will also be postponed. The Company will continue to work with the Auditor to complete the audit work as soon as practicable and will publish further announcement(s) to inform the shareholders of the Company of the date of the Board meeting as and when appropriate.

### **SUSPENSION OF TRADING**

Pursuant to Rule 13.50 of the Listing Rules, the Stock Exchange will normally require suspension of trading in an issuer's securities if an issuer fails to publish periodic financial information in accordance with the Listing Rules, and the suspension will normally remain in force until the issuer publishes an announcement containing the requisite financial information. In the event that the Company is unable to publish the 2023 Annual Results on or before 31 March 2024, it is expected that trading in the shares of the Company on the Stock Exchange will be suspended with effect from 9:00 a.m. on 2 April 2024 until the publication of the announcement in relation to the 2023 Annual Results by the Company.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Vital Innovations Holdings Limited**  
**Rong Xiuli**  
*Chairperson*

Hong Kong, 26 March 2024

*As at the date of this announcement, the Board of the Company comprises Ms. Rong Xiuli, Mr. Rong Shengli, Mr. Yin Xuquan and Mr. Wong Ho Chun as executive Directors; and Mr. Han Xiaojing, Mr. Wong Pong Chun James and Mr. Leung Man Fai as independent non-executive Directors.*